Novo Nordisk A/S Website

Novo Nordisk A/S

CPSE-NOVO B

Basic

  • Market Cap

    DKK 3,909.47B

  • EV

    DKK 3,927.09B

  • Shares Out

    4,434.52M

  • Revenue

    DKK 244.24B

  • Employees

    66,015

Margins

  • Gross

    84.65%

  • EBITDA

    48.25%

  • Operating

    45.38%

  • Pre-Tax

    45.8%

  • Net

    36.55%

  • FCF

    26.13%

Returns (5Yr Avg)

  • ROA

    30.08%

  • ROTA

    135.05%

  • ROE

    77.41%

  • ROCE

    78.87%

  • ROIC

    32.73%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    DKK 964.56

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    DKK 9,303M

  • Net Debt

    DKK 17.63B

  • Debt/Equity

    0.27

  • EBIT/Interest

    204.48

Growth (CAGR)

  • Rev 3Yr

    24.4%

  • Rev 5Yr

    16.42%

  • Rev 10Yr

    11.27%

  • Dil EPS 3Yr

    29.35%

  • Dil EPS 5Yr

    20.18%

  • Dil EPS 10Yr

    15.31%

  • Rev Fwd 2Yr

    23.19%

  • EBITDA Fwd 2Yr

    25.87%

  • EPS Fwd 2Yr

    24.61%

  • EPS LT Growth Est

    21%

Dividends

  • Yield

    —

  • Payout

    47.1%

  • DPS

    DKK 9.4

  • DPS Growth 3Yr

    27.36%

  • DPS Growth 5Yr

    18.2%

  • DPS Growth 10Yr

    15.37%

  • DPS Growth Fwd 2Yr

    24.56%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Metric
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23
LTM

Total Revenues

122,021

126,946

140,800

176,954

232,261

244,243

Total Revenues % Chg.

9.1%

4%

10.9%

25.7%

31.3%

29.7%

Cost of Goods Sold, Total

20,088

20,932

23,658

28,448

35,765

37,499

Gross Profit

101,933

106,014

117,142

148,506

196,496

206,744

Selling General & Admin Expenses, Total

35,830

36,886

41,058

50,684

61,598

62,528

R&D Expenses

14,220

15,462

17,199

23,287

31,029

32,907

Other Operating Expenses

-600

-460

-332

-1,034

-119

482

Other Operating Expenses, Total

49,450

51,888

57,925

72,937

92,508

95,917

Operating Income

52,483

54,126

59,217

75,569

103,988

110,827

Interest Expense, Total

-220

-390

-289

-378

-542

-542

Interest And Investment Income

65

337

231

239

1,069

1,069

Net Interest Expenses

-155

-53

-58

-139

527

527

Income (Loss) On Equity Invest.

—

-137

149

-24

-189

81

81

Currency Exchange Gains (Loss)

-3,212

-747

344

-4,651

1,652

1,785

Other Non Operating Income (Expenses)

-281

-150

-122

-181

-197

12

EBT, Excl. Unusual Items

48,698

53,325

59,357

70,409

106,051

113,232

Gain (Loss) On Sale Of Investments

-145

-195

296

-587

37

37

Gain (Loss) On Sale Of Assets

—

—

—

—

—

—

—

—

—

—

Asset Writedown

—

—

—

—

—

—

—

-573

-760

-1,414

-1,414

Other Unusual Items

—

—

—

—

—

—

—

—

—

—

EBT, Incl. Unusual Items

48,553

53,130

59,080

69,062

104,674

111,855

Income Tax Expense

9,602

10,992

11,323

13,537

20,991

22,579

Earnings From Continuing Operations

38,951

42,138

47,757

55,525

83,683

89,276

Net Income

38,951

42,138

47,757

55,525

83,683

89,276

Net Income to Common Incl Extra Items

38,951

42,138

47,757

55,525

83,683

89,276

Net Income to Common Excl. Extra Items

38,951

42,138

47,757

55,525

83,683

89,276

Total Shares Outstanding

4,704

4,625

4,557.8

4,500.7

4,458.3

4,459.6

Weighted Avg. Shares Outstanding

4,748.6

4,667.8

4,593.2

4,530.6

4,482.8

4,472.9

Weighted Avg. Shares Outstanding Dil

4,757.4

4,680

4,606.2

4,544.6

4,494.8

4,484.1

EPS

8.2

9

10.4

12.3

18.7

20

EPS Diluted

8.2

9

10.4

12.2

18.6

19.9

EBITDA

56,310

58,565

63,770

80,875

109,813

117,847

Effective Tax Rate

19.8%

20.7%

19.2%

19.6%

20.1%

20.2%